Clinical Trials

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

338 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04090034 2026-03-20

PRRT

50 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT07150546 2026-03-02

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Phase 1 Recruiting

15 enrolled

Phase 1 Active not recruiting

Gastro-enteropancreatic neuroendocrine tumor

NCT03833700 2026-02-27

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

70 enrolled

EndocrineGastrointestinalNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Desmoid Tumors, Adrenocortical Carcinoma

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT03972488 2026-01-21

NETTER-2

Phase 3 Active not recruiting

226 enrolled 14 charts

Gastro-enteropancreatic neuroendocrine tumor

NCT04505553 2026-01-21

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

Phase 2 Completed

78 enrolled 14 charts

Gastro-enteropancreatic neuroendocrine tumor, Anus Neoplasms, Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT06356467 2026-01-15

FARINET

450 enrolled

Phase 2 Active not recruiting

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT03891784 2026-01-14

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

NCT05987176 2026-01-14

NELMAS

Phase 2 Terminated

1 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT07302100 2025-12-24

DENUTNE

100 enrolled

Phase 2 Active not recruiting

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT03600233 2025-12-23

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

34 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05064150 2025-12-18

NET-PRO

Active not recruiting

2,539 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05364944 2025-11-17

OXTEND-01

Phase 1 Terminated

19 enrolled

Phase 3 Active not recruiting

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT05050942 2025-11-06

SORENTO

332 enrolled

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

Gastro-enteropancreatic neuroendocrine tumor

NCT06790706 2025-10-06

IMMUNORARE5

Phase 2 Recruiting

154 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT06256705 2025-09-22

OPERANDI-NET

Phase NA Recruiting

80 enrolled

Phase 3 Active not recruiting

Gastro-enteropancreatic neuroendocrine tumor

NCT04919226 2025-09-10

COMPOSE

259 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04609592 2025-09-09

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Phase 1 Recruiting

10 enrolled

Phase 1/2 Enrolling by invitation

Gastro-enteropancreatic neuroendocrine tumor

NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

52 enrolled

Phase 1 Active not recruiting

Gastro-enteropancreatic neuroendocrine tumor

NCT05262556 2025-08-07

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

15 enrolled

CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Phase 1/2 Completed

316 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT05196087 2025-07-02

NIP IT!

BreastDermatologicEndocrineGastrointestinalNET

500 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Breast Neoplasms, Melanoma, Neoplasm, Residual

NCT04986085 2025-03-28

NUTRIGETNE

399 enrolled 17 charts

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Phase 4 Completed

42 enrolled 11 charts

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT03980925 2025-01-13

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Phase 2 Completed

37 enrolled 25 charts

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT06253897 2024-12-24

BackSOM

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT04852679 2024-10-01

PALACE

Phase 3 Completed

43 enrolled 16 charts

Gastro-enteropancreatic neuroendocrine tumor

NCT05997056 2024-07-16

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Phase 2 Recruiting

21 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04893785 2024-06-18

CABOTEM

Phase 2 Recruiting

35 enrolled

Gastro-enteropancreatic neuroendocrine tumor

NCT05701241 2024-06-14

SAUNA

Phase 4 Recruiting

270 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT06402695 2024-05-07

ETNA-FPG

650 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04614766 2024-04-29

SPORE-3

Phase 1/2 Withdrawn

Phase EARLY_PHASE1 Unknown

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05359146 2024-04-19

Beta plus

16 enrolled

Gastro-enteropancreatic neuroendocrine tumor

NCT06155318 2023-12-20

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

300 enrolled

Gastro-enteropancreatic neuroendocrine tumor

NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Phase 2 Unknown

200 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05448157 2023-09-22

RGS-GEP-NET

Unknown

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell

NCT03043664 2023-06-29

PLANET

Phase 1/2 Completed

22 enrolled 12 charts

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

747 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Phase 2 Withdrawn

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

NCT01423734 2023-01-23

The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

Gastro-enteropancreatic neuroendocrine tumor

NCT04949282 2022-12-23

SEPTRALU

5,000 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pancreatic Diseases, Pancreatic Neoplasms, Stomach Neoplasms, Neuroectodermal Tumors, Neuroendocrine Tumors

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

Phase 4 Withdrawn

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

NCT02948946 2021-08-04

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors